O	0	7	RESULTS	RESULTS	NNS	B-NP

O	8	13	Forty	Forty	CD	B-NP
O	14	24	Caucasians	Caucasian	NNS	I-NP
O	25	26	(	(	(	O
O	26	28	19	19	CD	B-NP
O	29	36	females	female	NNS	I-NP
O	36	37	)	)	)	O
O	38	42	with	with	IN	B-PP
O	43	52	essential	essential	JJ	B-NP
O	53	65	hypertension	hypertension	NN	I-NP
O	66	70	were	be	VBD	B-VP
O	71	79	enrolled	enrol	VBN	I-VP
O	80	82	in	in	IN	B-PP
O	83	86	the	the	DT	B-NP
O	87	92	study	study	NN	I-NP
O	92	93	.	.	.	O

O	94	99	Their	Their	PRP$	B-NP
O	100	104	mean	mean	JJ	I-NP
O	105	108	age	age	NN	I-NP
O	109	112	was	be	VBD	B-VP
O	113	115	57	57	CD	B-NP
O	116	121	years	year	NNS	I-NP
O	121	122	.	.	.	O

O	123	127	Most	Most	JJS	B-NP
O	128	130	of	of	IN	B-PP
O	131	135	them	them	PRP	B-NP
O	136	140	were	be	VBD	B-VP
O	141	151	overweight	overweight	JJ	B-ADJP
O	151	152	,	,	,	O
O	153	155	17	17	CD	B-NP
O	156	159	had	have	VBD	B-VP
O	160	169	metabolic	metabolic	JJ	B-NP
O	170	178	syndrome	syndrome	NN	I-NP
O	179	188	according	accord	VBG	B-PP
O	189	191	to	to	TO	B-PP
O	192	195	the	the	DT	B-NP
O	196	203	updated	update	VBN	I-NP
O	204	207	AHA	AHA	NN	I-NP
O	208	213	NHLBI	NHLBI	NN	I-NP
O	214	223	statement	statement	NN	I-NP
O	224	225	(	(	(	O
O	225	232	defined	define	VBN	B-VP
O	233	235	as	as	IN	B-PP
O	236	237	3	3	CD	B-NP
O	238	240	or	or	CC	I-NP
O	241	245	more	more	JJR	I-NP
O	246	248	of	of	IN	B-PP
O	249	252	the	the	DT	B-NP
O	253	262	following	following	NN	I-NP
O	262	263	:	:	:	O
O	264	269	waist	waist	NN	B-NP
O	270	283	circumference	circumference	NN	I-NP
O	284	285	>	>	SYM	O
O	286	289	102	102	CD	B-NP
O	290	292	cm	cm	NN	I-NP
O	293	295	in	in	IN	B-PP
O	296	299	men	man	NNS	B-NP
O	300	303	and	and	CC	O
O	304	305	>	>	JJR	B-NP
O	306	308	88	88	CD	I-NP
O	309	311	cm	cm	NN	I-NP
O	312	314	in	in	IN	B-PP
O	315	320	women	woman	NNS	B-NP
O	320	321	,	,	,	O
B-Organism_substance	322	327	blood	blood	NN	B-NP
O	328	336	pressure	pressure	NN	I-NP
O	337	338	>	>	SYM	B-NP
O	338	339	=	=	SYM	B-VP
O	340	343	130	130	CD	B-NP
O	343	344	/	/	SYM	B-NP
O	344	346	85	85	CD	I-NP
O	347	351	mmHg	mmHg	NN	I-NP
O	351	352	,	,	,	O
O	353	366	triglycerides	triglyceride	NNS	B-NP
O	367	368	>	>	SYM	O
O	369	372	150	150	CD	B-NP
O	373	375	mg	mg	NN	I-NP
O	375	376	/	/	SYM	O
O	376	378	dl	dl	NN	B-NP
O	378	379	,	,	,	O
O	380	383	HDL	HDL	NN	B-NP
O	383	384	-	-	HYPH	I-NP
O	384	385	C	C	NN	I-NP
O	386	387	<	<	SYM	I-NP
O	388	390	40	40	CD	I-NP
O	391	393	mg	mg	NN	I-NP
O	393	394	/	/	SYM	B-NP
O	394	396	dl	dl	NN	I-NP
O	397	399	in	in	IN	B-PP
O	400	403	men	man	NNS	B-NP
O	404	407	and	and	CC	O
O	408	409	<	<	JJR	B-NP
O	410	412	50	50	CD	I-NP
O	413	415	mg	mg	NN	I-NP
O	415	416	/	/	SYM	B-NP
O	416	418	dl	dl	NN	I-NP
O	419	421	in	in	IN	B-PP
O	422	427	women	woman	NNS	B-NP
O	427	428	,	,	,	O
O	429	432	and	and	CC	O
O	433	440	fasting	fast	VBG	B-VP
O	441	448	glucose	glucose	NN	B-NP
O	449	450	>	>	SYM	B-NP
O	450	451	=	=	SYM	B-VP
O	452	455	100	100	CD	B-NP
O	456	458	mg	mg	NN	I-NP
O	458	459	/	/	SYM	B-NP
O	459	461	dl	dl	NN	I-NP
O	461	462	)	)	)	O
O	462	463	,	,	,	O
O	464	465	8	8	CD	B-NP
O	466	469	had	have	VBD	B-VP
O	470	474	type	type	NN	B-NP
O	475	476	2	2	CD	I-NP
O	477	485	diabetes	diabete	NNS	I-NP
O	486	489	and	and	CC	O
O	490	492	18	18	CD	B-NP
O	493	497	were	be	VBD	B-VP
O	498	505	smokers	smoker	NNS	B-NP
O	506	507	(	(	(	O
O	507	512	Table	Table	JJ	B-NP
O	513	514	1	1	CD	I-NP
O	514	515	)	)	)	O
O	515	516	.	.	.	O

O	517	527	Eprosartan	Eprosartan	NNP	B-NP
O	528	535	reduced	reduce	VBD	B-VP
O	536	539	SBP	SBP	NN	B-NP
O	540	542	by	by	IN	B-PP
O	543	544	8	8	CD	B-NP
O	544	545	%	%	NN	I-NP
O	546	547	(	(	(	O
O	547	548	p	p	NN	B-NP
O	548	549	<	<	SYM	B-ADJP
O	549	550	0	0	CD	B-NP
O	550	551	.	.	.	I-NP
O	551	554	001	001	CD	I-NP
O	554	555	)	)	)	O
O	556	559	and	and	CC	O
O	560	563	DBP	DBP	NN	B-NP
O	564	566	by	by	IN	B-PP
O	567	569	13	13	CD	B-NP
O	569	570	%	%	NN	I-NP
O	571	572	(	(	(	O
O	572	573	p	p	NN	B-NP
O	573	574	<	<	SYM	B-ADJP
O	574	575	0	0	CD	B-NP
O	575	576	.	.	.	I-NP
O	576	579	001	001	CD	I-NP
O	579	580	)	)	)	O
O	580	581	,	,	,	O
O	582	587	while	while	IN	B-SBAR
O	588	590	it	it	PRP	B-NP
O	591	594	had	have	VBD	B-VP
O	595	596	a	a	DT	B-NP
O	597	604	neutral	neutral	JJ	I-NP
O	605	611	effect	effect	NN	I-NP
O	612	614	on	on	IN	B-PP
O	615	618	the	the	DT	B-NP
O	619	624	lipid	lipid	NN	I-NP
O	625	632	profile	profile	NN	I-NP
O	633	636	and	and	CC	I-NP
O	637	651	apolipoprotein	apolipoprotein	NN	I-NP
O	652	658	levels	level	NNS	I-NP
O	659	660	(	(	(	O
O	660	666	Table2	Table2	NN	B-NP
O	666	667	)	)	)	O
O	667	668	.	.	.	O

O	669	679	Eprosartan	Eprosartan	NNP	B-NP
O	680	683	did	do	VBD	B-VP
O	684	687	not	not	RB	I-VP
O	688	694	affect	affect	VB	I-VP
B-Organism_substance	695	701	plasma	plasma	NN	B-NP
O	702	703	8	8	CD	I-NP
O	703	704	-	-	HYPH	I-NP
O	704	712	epiPGF2a	epiPGF2a	NN	I-NP
O	713	719	levels	level	NNS	I-NP
O	719	720	,	,	,	O
O	721	728	whereas	whereas	IN	O
O	729	731	it	it	PRP	B-NP
O	732	745	significantly	significantly	RB	B-ADVP
O	746	755	increased	increase	VBD	B-VP
O	756	758	by	by	IN	B-PP
O	759	761	24	24	CD	B-NP
O	761	762	%	%	NN	I-NP
O	763	766	the	the	DT	B-NP
O	767	770	lag	lag	NN	I-NP
O	771	775	time	time	NN	I-NP
O	776	778	of	of	IN	B-PP
O	779	784	total	total	JJ	B-NP
B-Organism_substance	785	790	serum	serum	NN	I-NP
O	791	800	oxidation	oxidation	NN	I-NP
O	801	802	(	(	(	O
O	802	805	145	145	CD	B-NP
O	806	807	+	+	SYM	O
O	807	808	/	/	SYM	O
O	808	809	-	-	SYM	O
O	810	812	54	54	CD	B-NP
O	813	816	min	min	NN	I-NP
O	817	819	vs	vs	IN	B-PP
O	820	823	180	180	CD	B-NP
O	824	825	+	+	SYM	O
O	825	826	/	/	SYM	O
O	826	827	-	-	SYM	O
O	828	830	58	58	CD	B-NP
O	831	834	min	min	NN	I-NP
O	834	835	,	,	,	O
O	836	837	p	p	NN	B-NP
O	837	838	=	=	SYM	B-VP
O	838	839	0	0	CD	B-NP
O	839	840	.	.	SYM	I-NP
O	840	843	001	001	CD	I-NP
O	843	844	)	)	)	O
O	845	846	(	(	(	O
O	846	852	Table2	Table2	NN	B-NP
O	852	853	)	)	)	O
O	853	854	.	.	.	O

O	855	865	Eprosartan	Eprosartan	NN	B-NP
O	866	873	reduced	reduce	VBN	B-VP
O	874	876	by	by	IN	B-PP
O	877	879	14	14	CD	B-NP
O	879	880	%	%	NN	I-NP
O	881	884	the	the	DT	B-NP
O	885	894	aspartate	aspartate	NN	I-NP
O	895	911	aminotransferase	aminotransferase	NN	I-NP
O	912	913	(	(	(	O
O	913	917	form	form	NN	B-NP
O	918	920	21	21	CD	I-NP
O	921	923	to	to	TO	I-NP
O	924	926	18	18	CD	I-NP
O	927	928	U	U	NN	I-NP
O	928	929	/	/	SYM	O
O	929	930	L	L	NN	B-NP
O	930	931	,	,	,	O
O	932	933	p	p	NN	B-NP
O	933	934	=	=	SYM	B-VP
O	934	935	0	0	CD	B-NP
O	935	936	.	.	SYM	I-NP
O	936	938	04	04	CD	I-NP
O	938	939	)	)	)	O
O	940	943	and	and	CC	O
O	944	946	by	by	IN	B-PP
O	947	949	21	21	CD	B-NP
O	949	950	%	%	NN	I-NP
O	951	954	the	the	DT	B-NP
O	955	962	alanine	alanine	NN	I-NP
O	963	979	aminotransferase	aminotransferase	NN	I-NP
O	980	981	(	(	(	O
O	981	985	from	from	IN	B-PP
O	986	988	24	24	CD	B-NP
O	989	991	to	to	TO	I-NP
O	992	994	19	19	CD	I-NP
O	995	996	U	U	NN	I-NP
O	996	997	/	/	SYM	O
O	997	998	L	L	NN	B-NP
O	998	999	,	,	,	O
O	1000	1001	p	p	NN	B-NP
O	1001	1002	=	=	SYM	B-VP
O	1002	1003	0	0	CD	B-NP
O	1003	1004	.	.	SYM	I-NP
O	1004	1006	05	05	CD	I-NP
O	1006	1007	)	)	)	O
O	1008	1016	activity	activity	NN	B-NP
O	1017	1018	(	(	(	O
O	1018	1024	Table2	Table2	NN	B-NP
O	1024	1025	)	)	)	O
O	1025	1026	.	.	.	O

O	1027	1030	The	The	DT	B-NP
O	1031	1045	administration	administration	NN	I-NP
O	1046	1048	of	of	IN	B-PP
O	1049	1059	eprosartan	eprosartan	NN	B-NP
O	1060	1063	had	have	VBD	B-VP
O	1064	1066	no	no	DT	B-NP
O	1067	1076	influence	influence	NN	I-NP
O	1077	1079	on	on	IN	B-PP
O	1080	1087	glucose	glucose	NN	B-NP
O	1088	1099	homeostasis	homeostasis	NN	I-NP
O	1099	1100	,	,	,	O
O	1101	1103	as	as	RB	B-CONJP
O	1104	1108	well	well	RB	I-CONJP
O	1109	1111	as	as	IN	I-CONJP
O	1112	1114	on	on	IN	B-PP
O	1115	1125	creatinine	creatinine	NN	B-NP
O	1126	1129	and	and	CC	O
O	1130	1134	uric	uric	JJ	B-NP
O	1135	1139	acid	acid	NN	I-NP
O	1140	1146	levels	level	NNS	I-NP
O	1147	1148	(	(	(	O
O	1148	1154	Table2	Table2	NN	B-NP
O	1154	1155	)	)	)	O
O	1155	1156	.	.	.	O

O	1157	1159	In	In	IN	B-PP
O	1160	1168	addition	addition	NN	B-NP
O	1168	1169	,	,	,	O
O	1170	1180	eprosartan	eprosartan	NN	B-NP
O	1181	1184	did	do	VBD	B-VP
O	1185	1188	not	not	RB	I-VP
O	1189	1195	affect	affect	VB	I-VP
O	1196	1204	clotting	clotting	NN	B-NP
O	1205	1207	or	or	CC	O
O	1208	1220	fibrinolytic	fibrinolytic	JJ	B-NP
O	1221	1229	activity	activity	NN	I-NP
O	1230	1232	as	as	IN	B-PP
O	1233	1237	this	this	DT	B-NP
O	1238	1241	was	be	VBD	B-VP
O	1242	1251	estimated	estimate	VBN	I-VP
O	1252	1254	by	by	IN	B-PP
O	1255	1258	PAI	PAI	NN	B-NP
O	1258	1259	-	-	HYPH	B-NP
O	1259	1260	1	1	CD	I-NP
O	1260	1261	,	,	,	I-NP
O	1262	1265	tPA	tPA	NN	I-NP
O	1266	1269	and	and	CC	I-NP
O	1270	1272	a2	a2	NN	I-NP
O	1272	1273	-	-	HYPH	O
O	1273	1284	antiplasmin	antiplasmin	NN	B-NP
O	1285	1286	(	(	(	O
O	1286	1292	Table2	Table2	NN	B-NP
O	1292	1293	)	)	)	O
O	1293	1294	.	.	.	O

O	1295	1298	The	The	DT	B-NP
O	1299	1308	enzymatic	enzymatic	JJ	I-NP
O	1309	1317	activity	activity	NN	I-NP
O	1318	1320	of	of	IN	B-PP
O	1321	1323	Lp	Lp	NN	B-NP
O	1323	1324	-	-	HYPH	B-NP
O	1324	1328	PLA2	PLA2	NN	I-NP
O	1329	1332	and	and	CC	I-NP
O	1333	1337	PON1	PON1	NN	I-NP
O	1338	1342	were	be	VBD	B-VP
O	1343	1346	not	not	RB	I-VP
O	1347	1354	altered	alter	VBN	I-VP
O	1355	1368	significantly	significantly	RB	B-ADVP
O	1369	1378	following	follow	VBG	B-PP
O	1379	1389	eprosartan	eprosartan	NN	B-NP
O	1390	1399	treatment	treatment	NN	I-NP
O	1400	1401	(	(	(	O
O	1401	1407	Table2	Table2	NN	B-NP
O	1407	1408	)	)	)	O
O	1408	1409	.	.	.	O

